Dr Bill Ketelbey
@billketelbey
CEO & Managing Director $ACW
ID: 2929502611
http://www.actinogen.com.au/home/ 14-12-2014 08:59:00
518 Tweet
269 Followers
74 Following
Dr Bill Ketelbey of Actinogen Medical (#ASX $ACW) will provide an update on the clinical development plans for Xanamem during a conference call on Monday, 19 Oct at 11.00am AEDT. Pre-register here s1.c-conf.com/DiamondPass/10…
Join us for live webcast starting in 15 mins 11.00am AEDT. @BillKetelbey will provide an overview of the new indication in #FragileX syndrome, planned #Alzheimers & #FXS ph II clinical trials, and the capital raising to support Alzheimer’s trial. #investor services.choruscall.com.au/webcast/actino…
WATCH WEBCAST > Actinogen hosted a conference call on Monday, 19 October 2020 with an update on the clinical development plans for Xanamem. @BillKetelbey Actinogen Medical $ACW #investor #clinicaltrials youtu.be/NdfQWvVLTY4
Fragile X syndrome is a rare genetic disorder, usually diagnosed around 3-5 years of age and characterised by a range of intellectual, developmental, and behavioural issues. #fragilex #fxs Dr Bill Ketelbey View our website to learn more actinogen.com.au/fragile-x-synd…
Register for Monsoon Communications Morning Twilight Briefing Webinar on 28 Oct 2020 11:00AM to hear the latest clinical development plans from Dr Bill Ketelbey, CEO & MD, Actinogen Medical #investor $ACW us02web.zoom.us/webinar/regist…
Dr @BillKetelbey is presenting 11.00am today at Monsoon Communications Morning Twilight Briefing Webinar. REGISTER #investor Actinogen Medical $ACW us02web.zoom.us/webinar/regist…
Dr Bill Ketelbey provided a clinical development update at the Morning Twilight Investor Briefing webinar – watch it from 17:50 $ACW #investor Monsoon Communications us02web.zoom.us/rec/play/DmWcF…
BoardroomMedia CEO, Will Canty speaks with Actinogen Medical (#ASX $ACW) CEO, Dr Bill Ketelbey about the upcoming clinical trial in Fragile X syndrome. We are delighted to be involved in this area of research… said Dr Bill Ketelbey #fragilex #investor boardroom.media/broadcast?eid=…
ASX: ACW World first medical trial Fragile X Syndrome WATCH: We speak with Actinogen Medical (ASX:ACW) CEO & Managing Director, Dr Dr Bill Ketelbey about the first medical trial of Fragile X syndrome. boardroom.media/broadcast-sing… #clinicaltrials #fragilexsyndrome #investor #Actinogen
FXS is caused by a mutation to the FMR1 gene located on the X chromosome. This mutation ‘switches the FMR1 gene off’ and prevents normal brain development. It is the most common cause of genetically inherited intellectual disability. #fragilex #fxs Dr Bill Ketelbey
Actinogen Medical files two new patent applications. “Strengthening our IP portfolio and extending the patent life of protection over Xanamem is aligned with our broader commercialisation strategy for Xanamem…” Dr Bill Ketelbey $ACW #investor View Announcement actinogen.com.au/wp-content/upl…
WATCH Dr Bill Ketelbey chats with Rachael Jones at Finance News Network providing an update on Actinogen’s lead drug candidate #Xanamem, its clinical trial roadmap and entitlement offer to raise up to $4.9m. Actinogen Medical #investor #ASX $ACW
REGISTER TODAY | Our CEO, Dr Bill Ketelbey, will be presenting at Switzer Small & Micro Cap Virtual Investor Day on 1 Dec 2020 #Investor #ASX $ACW Actinogen Medical zoom.us/webinar/regist…
Read Dr Boreham's Crucible David Langsam. Get a brief history of Actinogen Medical & discover what's next. Actinogen completed a capital raising to support the company through a follow-up #Alzheimers trial, as well as for the new indication #FragileX syndrome bit.ly/ACW-BD-20Nov
It’s not too late to register. Dr Bill Ketelbey will provide some insight on Actinogen Medical & the Company’s lead drug, Xanamem, designed to enhance cognition through inhibiting cortisol production in the brain, in #Alzheimers & other diseases Switzer zoom.us/webinar/regist…
Actinogen Medical is pleased with the many key milestones achieved in 2020. We are pleased to provide an end-of-year review and an outlook update from Dr Bill Ketelbey. View Announcement #investor #alzheimers #fxs #diabetes #schizophrenia #clinialtrials $ACW bit.ly/2WpA6cy
Actinogen Medical submitted quarterly activity report & Appendix 4C for period ended 31 Dec 2020. Actinogen is advancing the development of #Xanamem in the treatment of serious and debilitating conditions with a high unmet medical need. #ASX $ACW #investor actinogen.com.au/wp-content/upl…
We are pleased to announce the FDA has granted Actinogen Medical drug #Xanamem Rare Paediatric Disease Designation (RPDD) for treatment of #FXS. RPDD provides for priority review, accelerating marketing approval, & a second tradeable priority review voucher. bit.ly/3azZCmb
The US FDA has granted Actinogen’s drug #Xanamem, RPDD for treatment of FXS in patients under 18 years. “We have devoted increased resources to broadening Xanamem’s clinical development pipeline, with FXS selected as second indication…” said Dr Bill Ketelbey bit.ly/3azZCmb
